Themis Medicare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Themis Medicare reported a significant decline in standalone performance for FY2026, with revenue falling 15.6% to Rs 34,223.55 Lakhs from Rs 40,551.16 Lakhs in the prior year. The company swung to a standalone net loss of Rs 1,418.55 Lakhs compared to a profit of Rs 2,392.15 Lakhs in FY2025. Consolidated PAT attributable to equity holders also dropped sharply to Rs 114.39 Lakhs from Rs 2,983.30 Lakhs in the prior year. Exceptional items totaling Rs 215.92 Lakhs (Labour Code impact of Rs 86.53 Lakhs and write-off of investment/receivables of Rs 129.39 Lakhs) contributed to the standalone loss. The Board recommended a dividend of Rs 0.50 per share (50% on face value of Re. 1). Auditors Krishaan & Co. issued a clean unqualified opinion with no going concern or emphasis of matter notes.
The company experienced a dramatic turnaround from profit to loss on standalone basis, with both revenue contraction and one-time exceptional write-offs weighing heavily on FY2026 results. Despite the loss, the dividend recommendation and clean auditor opinion provide some investor comfort, though the stock may face near-term pressure given the steep decline in profitability.